Virtual screening (VS) is a computational technique used in drug discovery to search libraries of small molecules in order to identify those structures which are most likely to bind to a drug target, typically a protein receptor or enzyme.
Compared to traditional experimental High-Throughput Screening (HTS), in silico virtual screening offers a cost-effective and rapid alternative for early-stage drug discovery.
Our computational screening solutions cover a wide range of therapeutic targets and discovery scenarios.
Targeting signaling pathways.
Addressing complex membrane proteins.
Protein-Protein Interaction modulation.
Combatting infectious diseases.
Target-focused computational strategies designed to address specific drug discovery challenges.
High-throughput identification of potent inhibitors. We optimize hit rates for standard binding pockets using advanced algorithms.
Learn moreSpecialized screening for peptide therapeutics and biologics, accounting for flexibility and large surface interactions.
Learn moreCurate focused libraries tailored to your target. We filter for drug-likeness and diversity to maximize efficiency.
Learn moreAddress polypharmacology and repurposing by screening compounds against multiple targets simultaneously.
Learn more
Discover the perfect library for your target. Our catalog covers comprehensive specifications for Bioactive, Natural Product, and Fragment libraries tailored for drug discovery.
Download PDF BrochureWe employ advanced algorithms and high-performance computing to offer comprehensive computational screening services. Select a service below to learn more.
Target Identification & Drug Repositioning
Identify potential protein targets for a given small molecule with our advanced "Target Fishing" approach. Our inverse screening (Reverse Docking) platform screens your compound against a vast database of the druggable proteome.
This service is critical for drug repositioning, elucidating the mechanism of action for phenotypic hits, and predicting potential toxicity by identifying off-target interactions early in the discovery process.
Read MoreScreening Without Structure
Ideally suited for targets where the crystal structure is unavailable or highly flexible. We leverage the chemical features of known active ligands to identify novel hits.
By utilizing shape similarity search, molecular fingerprinting, and advanced QSAR modeling, we can efficiently enrich compound libraries with scaffolds that possess high structural or electrostatic similarity to your reference compounds.
Read MoreHigh-Precision Molecular Docking
When the 3D structure of the target is available, our SBVS service provides the most direct method for hit identification. We utilize high-performance docking algorithms to predict the preferred binding orientation and affinity of millions of small molecules.
Our workflow includes ensemble docking to account for protein flexibility and consensus scoring to minimize false positives, delivering a high-quality list of candidates for experimental testing.
Read MoreExploring Chemical Space Efficiently
Screening low molecular weight compounds (fragments) allows for a more efficient exploration of chemical space compared to HTS. This method is particularly effective for "undruggable" or challenging targets.
We identify weak but specific binders with high ligand efficiency, which can then be grown or linked into potent lead compounds using structural guidance, offering a robust starting point for lead generation.
Read MoreScaffold Hopping & abstract Design
We construct precise 3D pharmacophore models defined by the spatial arrangement of essential features (hydrogen bond donors/acceptors, hydrophobic regions) required for binding.
This abstract method is powerful for "scaffold hopping," allowing us to identify structurally diverse chemotypes that share the same biological activity profile but possess improved physicochemical properties or novel intellectual property positions.
Read MoreAccess our diverse and high-quality compound libraries, ranging from bioactive molecules to fragment-based collections.
| Library Category | Available Collections & Specifications |
|---|---|
|
Bioactive Compound Library
Drug Repurposing Compound Library
Featured Novel Bioactive Compound Library
Disease-Specific Collections
Target-Focused Libraries (GPCR, Kinase, etc.)
Approved Drug Library
|
|
|
Disease-Functional Natural Products
Activity-classified Natural Product Library
Structure-classified Natural Product Library
Natural Product Derivatives Libraries
High-Throughput Screening (HTS) Natural Products
|
|
|
High-Diversity Drug-Like Library
CNS-Penetrant Library
Macrocyclic Compounds
Potential Disease Targets
Pathway-Focused Screening Sets
|
|
|
General Fragment Library (Ro3 Compliant)
Drug-Fragment Library
High Solubility 3D Diversity Fragment Library
Featured Fragments
High Solubility Micro Fragment Library
Carboxylic Acid Fragment Library
Mini Electrophilic Heterocyclic Fragment Library
|
A systematic in silico screening workflow ensures the efficient identification of high-quality hits from compound libraries.
Curation of small molecule libraries (e.g., ZINC, ChEMBL, or custom libraries). Filtering for drug-like properties (Lipinski's Rule of 5) and ADMET criteria.
Binding pocket identification and preparation. We analyze the receptor for druggability and flexibility to ensure accurate docking.
High-throughput docking of millions of compounds. We use advanced scoring functions to rank compounds based on predicted binding affinity.
Post-screening analysis including visual inspection of binding modes and hit prioritization for experimental validation.
We provide accurate, reliable, and scalable in silico screening solutions tailored to your drug discovery needs.
We provide comprehensive data and reports to facilitate your downstream experimental assays.
Contact our computational drug discovery experts today to start your virtual screening project.
Talk to our technical team about your project!
I Want To Talk